Drug Profile
TI 1007
Alternative Names: CAR-T/CD19 - Timmune Biotech; CAR-T/CD19 with TriTE - Timmune Biotech; CD19-TriCAR-T; TI-1007; TriCAR-T-CD19 adoptive immunotherapy - Timmune BiotechLatest Information Update: 13 Jul 2022
Price :
$50
*
At a glance
- Originator Timmune Biotech
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- Phase I Leukaemia
Most Recent Events
- 13 Jul 2022 Phase I development Leukaemia (Combination therapy, In adolescents, In children, Second-line therapy or greater) is ongoing in China (IV, Infusion) (NCT03910842)
- 13 Jul 2022 Phase I development Non-Hodgkin's-lymphoma (Combination therapy, In adolescents, In children, Second-line therapy or greater) is ongoing in China (IV, Infusion) (NCT03910842)
- 28 May 2022 No recent reports of development identified for phase-I development in Leukaemia(Combination therapy, In adolescents, In children, Second-line therapy or greater) in China (IV, Infusion)